Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
The Australian patent represents the first patent granted for the Company's new point-of-care testing platform Co-Diagnostics, Inc., a Utah company, has received a patent in the Australian Patent No. AU2022270084A1 for its new point-of-care testing platform, Co-Dx PCR Platform Technologies. The patent is the first granted for the new platform and provides broad protection in Australia for the Company’s proprietary system and methods used for nucleic acid detection and analysis. The claims specifically cover the design and operation of the Co.Dx PC Pro™ instrument and test cups. This patent represents a significant milestone in securing global protection for CoDx's technology and is seen as a key defensive measure to protect the commercial potential of the platform. The Co-DIagnostics platform is designed to deliver gold-standard PCR accuracy in a compact device suitable for decentralized testing environments.
Diterbitkan : 6 bulan lalu oleh Cision PR Newswire di dalam Tech
The Australian patent represents the first patent granted for the Company’s new point-of-care testing platform
SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx... [5026 symbols]
Topik: AI, Australia